The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Share News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.85
Bid: 48.70
Ask: 48.90
Change: -0.70 (-1.41%)
Spread: 0.20 (0.411%)
Open: 49.30
High: 49.40
Low: 48.35
Prev. Close: 49.55
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IP Group net asset value declines amid supply chain issues, inflation

Wed, 13th Mar 2024 11:02

(Alliance News) - IP Group PLC on Wednesday reported a slowed decline in net asset value, citing global issues such as supply chain disruptions and inflation and interest rate trends.

IP Group invests in companies pursuing breakthrough science and innovation, such as Oxford Nanopore Technologies PLC.

The company said net asset value per share declined 14% to 114.8 pence as at December 31 from 132.9p a year prior.

The contraction on return on NAV was 13% in 2023, compared to a decline of 20% in 2022.

Pretax loss narrowed 49% to GBP176.3 million from GBP343.5 million.

"We continue to monitor the impact of the ongoing wars in Ukraine and the Middle East, heightened geopolitical tension, supply chain disruption, inflation and interest rate trends, elevated levels of the cost of living and volatile capital markets," IP Group said. and note

It added that "the greatest impact to the group has been the marked decline in the valuation of technology and life sciences sector listed companies, which we consider heighten our principal risks of macroeconomic environment and access to capital risks."

The company proposed a final dividend to 0.76 pence per share, upped from 0.72p a year prior. This brought the total for 2023 to 1.27p, up 4.1% from 1.22p.

Looking ahead, IP Group cited opportunities to benefit from increased public policy support in the UK for science and innovation, with GBP109 million capital across the company's third party managed funds including its subsidiary Parkwalk Advisors.

Chief Executive Officer Greg Smith said: "The group and its portfolio remain well-funded and we are confident the group will reap the benefits of our maturing portfolio given the number of key milestones anticipated over the next 12 to 18 months, particularly in life sciences.

"The group is committed to delivering value for all stakeholders and anticipates that the next 18 months could be transformational to fair value growth."

IP Group shares fell 2.3% to 50.40 pence each on Wednesday morning in London.

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
15 Nov 2021 14:15

EXECUTIVE CHANGES: Halma hires non-exec; Diurnal names new chair

EXECUTIVE CHANGES: Halma hires non-exec; Diurnal names new chair

Read more
11 Nov 2021 14:57

IN BRIEF: Ceres Power strikes deal with IP Group investee RFC

IN BRIEF: Ceres Power strikes deal with IP Group investee RFC

Read more
11 Nov 2021 09:18

IP Group portfolio company inks joint development agreement with Ceres Power

(Sharecast News) - Intellectual property company IP Group said on Thursday that portfolio company RFC Power, a long-duration energy storage company, had signed a joint development agreement with fuel cell technology firm Ceres Power.

Read more
29 Oct 2021 14:36

IN BRIEF: IP Group investee Hinge Health valued at over USD6 billion

IN BRIEF: IP Group investee Hinge Health valued at over USD6 billion

Read more
25 Oct 2021 16:10

IN BRIEF: IP Group books GBP27.5 million fair value gain

IN BRIEF: IP Group books GBP27.5 million fair value gain

Read more
25 Oct 2021 08:42

IP Group records £27.5m value gain after recent funding round

(Sharecast News) - Intellectual property-based business developer IP Group said on Monday that, following the completion of a funding round by a portfolio company in its top 20 most valuable holdings, it recorded a net realised and unrealised fair value gain of about £27.5m, or 2.6p per share.

Read more
19 Oct 2021 10:50

Oxford BioMedica licences technology for cystic fibrosis treatment

Oxford BioMedica licences technology for cystic fibrosis treatment

Read more
19 Oct 2021 09:18

Boehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology

(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.

Read more
12 Oct 2021 14:40

IN BRIEF: Outgoing IP Group CEO Alan Aubrey buys 40,000 shares

IN BRIEF: Outgoing IP Group CEO Alan Aubrey buys 40,000 shares

Read more
6 Oct 2021 12:11

LONDON MARKET MIDDAY: Shares fall as gas prices fuel inflation fear

LONDON MARKET MIDDAY: Shares fall as gas prices fuel inflation fear

Read more
6 Oct 2021 09:26

IP Group CEO, CIO step down after Oxford Nanopore IPO

(Sharecast News) - IP Group said on Wednesday that chief executive Alan Aubrey and chief investment officer Mike Townend are retiring and stepping down from the board with immediate effect following the successful flotation of its largest holding, Oxford Nanopore Technologies.

Read more
6 Oct 2021 09:18

TOP NEWS: Oxford Nanopore IPO prompts change at top at IP Group

TOP NEWS: Oxford Nanopore IPO prompts change at top at IP Group

Read more
30 Sep 2021 12:11

LONDON MARKET MIDDAY: Stocks mixed; Oxford Nanopore soars on debut

LONDON MARKET MIDDAY: Stocks mixed; Oxford Nanopore soars on debut

Read more
30 Sep 2021 10:47

UPDATE: Oxford Nanopore nears GBP5 billion value in London debut

UPDATE: Oxford Nanopore nears GBP5 billion value in London debut

Read more
30 Sep 2021 10:42

Shares soar as Oxford Nanopore makes its London debut

(Sharecast News) - Shares in Oxford Nanopore Technologies surged on Thursday after the British biotech made its £3.4bn debut on the London Stock Exchange.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.